drugset / Trial / NCT01078675

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

NCT01078675

Phase 3 Completed 315 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being carried out to see if the study medication, rosuvastatin, is effective in treating familial hypercholesterolaemia in children and adolescents, and to determine the long term (over 2 years) safety, tolerability and efficacy of the study medication in these patients. This study will also measure levels of drug in the blood and see how well it is tolerated. This is known as pharmacokinetic (PK) analysis. At baseline only a small number of patients will participate in a single dose PK phase over 24 hours. In order to see if this medication works, a control group of healthy siblings will help the researchers to compare certain results.

Timeline

Start
2010-02
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 5 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral